Results 161 to 170 of about 44,321 (338)

Fully human antibody V_H domains to generate mono and bispecific CAR to target solid tumors [PDF]

, 2021
Guanmeng Wang, Xin Zhou, Giovanni Fucà, Elena Dukhovlinova, Peishun Shou, Hongxia Li, Colette M. Johnston, Brian McGuinness, Gianpietro Dotti, Hongwei Du   +9 more
openalex   +1 more source

Cancer‐Specific Antihuman Podoplanin Antibody chLpMab‐2f Exerts Antitumor Effects Against Pleural Mesothelioma

Cancer Science, EarlyView.
Cancer‐specific antihuman podoplanin antibody chLpMab‐2f exerted antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against pleural mesothelioma (PM) cell lines. Additionally, chLpMab‐2f inhibited tumor progression in mice with subcutaneously and intrathoracically transplanted human PM cells.
Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K. Kaneko, Yukinari Kato, Yasuhiko Nishioka   +15 more
wiley   +1 more source

Large scale controlled Fab exchange GMP process to prepare bispecific antibodies

Frontiers in Bioengineering and Biotechnology
Objective: Bispecific antibodies (BsAbs) have demonstrated significant therapeutic impacts for the treatment of a broad spectrum of diseases that include oncology, auto-immune, and infectious diseases.
Xia Yao, Mingquan Xie, Yinyin Ben, Yixiang Zhu, Gaoqiang Yang, Simon Chi Wai Kwong, Zhengliang Zhang, Mark L. Chiu, Mark L. Chiu   +8 more
doaj   +1 more source

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations [PDF]

, 2003
Immunostimulatory CpG oligodeoxynucleotides (ODNs) can enhance the therapeutic effect of monoclonal antibodies (mAbs) by enhancing antibody-dependent cell-mediated cytotoxicity (ADCC).
Bakker, A. (Annie), Bevaart, L., Dahle, C.E., Jansen, M.J.H. (Marco), Ojik, H.H. van, Vugt, M.J. van, Weiner, G.J., Winkel, J.G. van de   +7 more
core  

Silencing Fc Domains in T cell–Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency

, 2019
Linlin Wang, Sayed Shahabuddin Hoseini, Hong Xu, Vladimir Ponomarev, Nai‐Kong V. Cheung   +4 more
openalex   +2 more sources

Video S2B from Harnessing the hERG1/β1 Integrin Complex via a Novel Bispecific Single-chain Antibody: An Effective Strategy against Solid Cancers

, 2023
Claudia Duranti, Jessica Iorio, Tiziano Lottini, Elena Lastraioli, Silvia Crescioli, Giacomo Bagni, Matteo Lulli, Chiara Capitani, Rayhana Bouazzi, Matteo Stefanini, Laura Carraresi, Luisa Iamele, Hugo de Jonge, Annarosa Arcangeli   +13 more
openalex   +1 more source

Impact of Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors on Anti‐PD‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes

Cancer Science, EarlyView.
Ramucirumab (RAM) plus docetaxel (DOC) after PD‐1 inhibitors showed clinical activity, with responders exhibiting maintained anti–PD‐1 (IgG4+)‐bound CD8+ T cells and decreased IgG4+ Tregs. A sequential strategy of administering RAM plus DOC during persistent anti–PD‐1 antibody binding may be beneficial in patients with advanced non‐small cell lung ...
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, Motohiro Tamiya, Kazumi Nishino, Akihiro Tamiya, Kyoichi Okishio, Yuhei Kinehara, Tomoki Kuge, Masahide Mori, Shingo Satoh, Hidekazu Suzuki, Satoshi Tetsumoto, Toshie Niki, Yasuhiko Suga, Akio Osa, Toshiyuki Minami, Shohei Koyama, Yoshito Takeda, Nobuyuki Takakura, Atsushi Kumanogoh   +20 more
wiley   +1 more source

Homoharringtonine Promotes FTO Degradation to Suppress LILRB4‐Mediated Immune Evasion in Acute Monocytic Leukaemia

Cell Proliferation, EarlyView.
Homoharringtonine (HHT) suppresses immune evasion in acute monocytic leukaemia (AML‐M5) by attenuating the FTO/m6A/LILRB4 axis, thereby enhancing CD8+ T cell cytotoxicity. ABSTRACT Acute monocytic leukaemia, a subtype of acute myeloid leukaemia (AML), is a highly aggressive malignancy characterised by a poor prognosis, primarily due to the ability of ...
Fangfang Huang, Xiang Luo, Mengyu Zhang, Le Jin, Wenxin Sun, Peihan Chen, Xiuli Hong, Chenyu Xu, Meizhi Jiang, Die Hu, Bin Zhang, Shengwei Hu, Chuanjiang Yang, Rui Gao, Jinzhang Zeng, Quanyi Lu, Qiang Luo, Jun Wu, Siming Chen   +18 more
wiley   +1 more source

Supplementary Data from A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity [PDF]

, 2023
Leila M. Boustany, Sherry L. LaPorte, Laurie Wong, Clayton White, Veena Vinod, Joel Shen, Wendy Yu, David Koditek, Michael B. Winter, Stephen J. Moore, Mei Li, Linnea Diep, Yuanhui Huang, Shouchun Liu, Olga Vasiljeva, Jim West, Jennifer Richardson, Bryan Irving, Marcia Belvin, W. Michael Kavanaugh   +19 more
openalex   +1 more source

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source